Abivax completes $920 million public offering

Abivax SA, a clinical‑stage biotechnology company based in Paris, announced the closing of its underwritten public offering of 7,360,000 American Depositary Shares (ADS). The offering raised gross proceeds of approximately $920 million (€807.4 million) and net proceeds of about $874 million (€767.1 million) after underwriting fees and expenses.

The company said the net proceeds, together with its existing cash and cash equivalents, will fund its operations through the fourth quarter of 2029. Abivax’s ordinary shares trade on Euronext Paris under the symbol “ABVX” and its ADS trade on the Nasdaq Global Market under the same symbol. The offering was managed by Leerink Partners, Morgan Stanley, Piper Sandler and Guggenheim Securities, with Van Lanschot Kempen as lead manager. No stabilization activities were performed during the offering period.